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Gemﬁbrozil is a widely prescribed hypolipidemic agent in humans and a peroxisome proliferator and liver carcinogen in
rats. Three-month feed studies of gemﬁbrozil were conducted by the National Toxicology Program (NTP) in male Harlan
Sprague-Dawley rats, B6C3F1 mice, and Syrian hamsters, primarily to examine mechanisms of hepatocarcinogenicity. There
was morphologic evidence of peroxisome proliferation in rats and mice. Increased hepatocyte proliferation was observed in rats,
primarily at the earliest time point. Increases in peroxisomal enzyme activities were greatest in rats, intermediate in mice, and least
in hamsters. These studies demonstrate that rats are most responsive while hamsters are least responsive. These events are causally
related to hepatotoxicity and hepatocarcinogenicity of gemﬁbrozil in rodents via peroxisome proliferator activated receptor-α
(PPARα) activation; however, there is widespread evidence that activation of PPARα in humans results in expression of genes
involved in lipid metabolism, but not in hepatocellular proliferation.
1.Introduction
Gemﬁbrozil is a nonhalogenated derivative in the class of
drugs called ﬁbrates that include cloﬁbrate, fenoﬁbrate,
and ciproﬁbrate. Since its approval by the FDA in 1982,
it has been used extensively as a lipid-regulating drug
and is an eﬀective treatment of hypertriglyceridemia and
hypercholesterolemia. The results of two clinical trials
demonstrate that gemﬁbrozil has proven to be a valuable
therapeutic agent in the control of coronary heart disease
[1,2].Itappearsthatgemﬁbrozilexertshypolipidemiceﬀects
by decreasing the concentration of triglycerides [2]a n d
low-density lipoprotein cholesterol (“bad” cholesterol) [3]
and raising the concentration of high-density lipoprotein-
cholesterol (“good” cholesterol) [2, 3].
In rodents, gemﬁbrozil and other ﬁbrates are peroxisome
proliferators, inducing a syndrome that includes enlarged
livers associated with an increased number and size of
hepatic peroxisomes and induction of peroxisomal and
microsomal fatty acid-oxidizing enzymes including acyl
CoA oxidase, carnitine acetyltransferase, and cytochrome
P450 4A [4–7]. In addition to ﬁbrates, peroxisome pro-
liferators include selected herbicides, phthalate ester plas-
ticizers, and endogenous long chain fatty acids [5, 8].
Peroxisome proliferators are associated with hepatocarcino-
genicity in rodents. Studies with several peroxisome pro-
liferators, including Wy-14,643 ([4-chloro-6-(2,3-xylidino)-
2-pyrimidinylthio]acetic acid; the prototype peroxisome
proliferator), di (2-ethylhexyl) phthalate and gemﬁbrozil,
and cloﬁbrate have demonstrated carcinogenicity rodents
[9–14].
The basis for understanding the biology of peroxisome
proliferation in rodents and humans began with the dis-
covery of the peroxisome proliferator activated receptor-α
(PPARα) in 1990 [15]. Agonists for the PPARα were found
to induce a battery of genes, resulting in peroxisome pro-
liferation in the cytoplasm of rodent liver, which increased
lipid catabolism via induction of peroxisomal fatty acyl-CoA
β-oxidation. In humans, ﬁbrates including gemﬁbrozil bind
PPARα with high aﬃnity, producing reduction in plasma2 PPAR Research
triglycerides and increased HDL concentrations [16]. These
eﬀects are thought to result from reducing apoCIII expres-
sion and induction of apolipoprotein-AI and AII expression
in humans, which are under control of PPARα, and not
by proliferation of peroxisomes which occurs in rodents
[17] .T h em o l e c u l a rb a s i so fd i ﬀerences in response to the
hepatic eﬀects of peroxisome proliferators is hypothesized to
be a combination of quantitative diﬀerences in the hepatic
expression of PPARα and qualitative diﬀerences in the
pattern or functionality of the downstream events that are
regulated by the receptor [18, 19].
Although the biochemical and physiologic eﬀects asso-
ciated with hepatic peroxisome proliferation are thought
to play a role in the hepatic toxicity and carcinogenicity
in sensitive species of rodents, the mechanism of perox-
isome proliferator-induced tumorigenesis and the nature
of its species-selectivity are not understood [20–22]. The
results of a limited number of published studies suggest
that gemﬁbrozil is not mutagenic [12, 23]. As a result,
the observed hepatocarcinogenicity is thought to be the
result of indirect mechanisms. Mechanisms of PPARα-
induced hepatocarcinogenicity have been recently reviewed
[24]. Activation results in increase cell proliferation and
decreased apoptosis. PPARα-induced oxidative stress may
contribute to cell proliferation via increased signaling or may
damage DNA, resulting in the initiation of carcinogenesis;
the data for peroxisome proliferator-induced DNA damage
are conﬂicting [25, 26]. Peroxisome proliferator-induced
oxidative stress is thought to occur in the rodent because
treatment of rodents causes large increases in the activity of
the hydrogen peroxide producing peroxisomal β-oxidation
enzymes while causing only minimal increases in the activity
of peroxisomal catalase and decreased activity of glutathione
peroxidase [27–29]. One study with Wy-14,643 revealed
that hepatocarcinogenicity appears to correlate better with
cell proliferation rather than peroxisome proliferation [30].
PPARα null mice have been used to evaluate the role of
PPARα in rodent hepatocarcinogenicity. Wy-14,643 hepato-
carinogenicity was observed in wild type mice, but not in
null mice [31, 32]. In contrast, following exposure to di (2-
ethylhexyl) phthalate, more liver tumors were observed in
PPARnull mice compared to wild type mice [33], suggesting
that PPAR-independent mechanisms may also be active in
the hepatocarcinogenicity of some peroxisome proliferators.
Recently, Gonzalez and colleagues have published a series of
studies in wild type and humanized PPARα mice [25, 26,
32, 34, 35]. These studies demonstrate that the humanized
PPARα mice are resistant to hepatocellular proliferation
[25]a n dt u m o r s[ 32] following exposure to Wy-14,643. In
contrast, genes involved in peroxisomal and mitochondrial
β-oxidation are induced in the wild type and humanized
mice. These authors have concluded that the observed
diﬀerences in the hepatocellular response are the result of
diﬀerences in the disposition of let-7C microRNA (miRNA)
and c-myc expression. In the wild type mice, let-7C miRNA
is downregulated, resulting in the increased expression of c-
myc, hepatocellular proliferation, and tumors [26, 34, 35].
In contrast, neither downregulation of let-7C miRNA nor
increased expression of c-myc occurs in humanized PPARα
mice, resulting in a lack of hepatocellular proliferation and
tumors. These data may explain the diﬀerence in PPARα-
mediated eﬀects between rodents and humans.
The National Toxicology Program (NTP) conducted a
series of 3-month feed studies in male Harlan Sprague
Dawley rats, B6C3F1 mice, and Syrian hamsters to evaluate
mechanisms of hepatocarcinogenicity of peroxisome prolif-
erators; Wy-14,643 [36], gemﬁbrozil, dibutyl phthalate, and
2,4-dichlorophenoxyacetic acid. Gemﬁbrozil was included in
this initiative because it interacts with the PPARα in rodents
and humans as a mechanism of its pharmacological activity,
and it induces hepatomegaly, peroxisome proliferation, and
hepatocellular tumors in rodents. It was also of interest
to evaluate whether these adverse eﬀects were relevant to
humans taking this therapeutic agent chronically. Rats and
mice are commonly used in studies examining peroxisome
proliferators and males are typically more sensitive than
females. Hamsters were included because this species, like
humans,isbelievedtoberelativelyresistanttothehepatotox-
icity and carcinogenicity of peroxisome proliferators [37]. In
addition to standard endpoints, the studies included assess-
m e n t so fh e p a t o c y t ec e l lp r o l i f e r a t i o n ,p e r o x i s o m a le n z y m e
analysis, and analysis of lipid levels. Several investigators
were awarded RO3 grants to study mechanistic aspects of
peroxisome proliferator-induced hepatocarcinogenesis using
tissues available from these studies [38–44]. The purpose of
this manuscript is to present the eﬀects of gemﬁbrozil on
hepatic toxicity and lipid metabolism following exposure of
rats, mice, and hamsters following subchronic exposure in
feed, in the context of the NTP studies of Wy-14,643 [36].
2.MaterialsandMethods
2.1. Chemical and Dose Formulations. Gemﬁbrozil was
obtained from Sigma Chemical Company (St. Louis, MO)
in three lots. Lot 18F0334 was identiﬁed as gemﬁbrozil by
infrared spectroscopy (IR) and proton nuclear magnetic
resonancespectroscopy(NMR).Puritywasdeterminedtobe
>99% by high performance liquid chromatography (HPLC).
Lot 02H0074 was found to be 98.7% pure by HPLC. Lots
18F0334 and 02H0074 were combined prior to the study
and renamed as lot S040794. Purity of the combined lot was
determined to be >99% by HPLC. A third lot, 104H0551,
was identiﬁed by IR. Prior to the study the purity of lot
S040794 and lot 104H0551 relative to a frozen reference
sample of each lot was determined by HPLC to be 103.4%
and 99%, respectively. Both of these lots were used in the 90-
day studies. To ensure stability, the bulk chemical was stored
in amber glass bottles sealed with Teﬂon-lined lids or sealed
buckets lined with double Teﬂon bags, protected from light,
at room temperature. During the studies, periodic reanalyses
against frozen reference samples using HPLC revealed no
degradation of the bulk chemical. Dose formulations were
prepared by mixing gemﬁbrozil with feed and were stored
in plastic buckets at approximately 5◦Cf o ru pt o3w e e k s .
Homogeneity of selected dose formulations was conﬁrmed
byHPLC.Doseformulationswereanalyzedatthebeginning,
midpoint, and end of the studies. Of the dose formulationsPPAR Research 3
analyzed for rats, mice, and hamsters, 96% (26/27) were
within 10% of the target concentrations.
2.2. Animals and Animal Maintenance. The studies were
conducted at Battelle Columbus Laboratories (Columbus,
OH) in compliance with Food and Drug Administration
Good Laboratory Practice Regulations (21 CFR, Part 58).
Male Sprague-Dawley rats were obtained from Harlan
Sprague-Dawley, Inc. (Indianapolis, IN). Male B6C3F1 mice
were obtained from Taconic Farms, Inc. (Germantown,
NY). Male Syrian hamsters were obtained from Frederick
Cancer Research and Development Center (Frederick, MD).
Study animals were provided NTP-2000 open formula mean
diet (Ziegler Brothers, Inc., Gardners, PA) and tap water
(via automatic watering system) ad libitum. Animals were
quarantined for approximately two weeks prior to the start
of the studies and were approximately 8 weeks (rats and
mice) or 7 weeks old (hamsters) on the ﬁrst day of dosing.
Study animals were distributed randomly into groups of
approximate initial mean body weight and identiﬁed by
tail tattoo (rats and mice) or ear tag (hamsters). Rats were
housed ﬁve animals per cage. Mice and hamsters were
housed individually. The animal room was maintained at a
temperature of 72 ± 3◦C, a relative humidity of 50 ± 15%, a
light/dark cycle of 12 hours (ﬂuorescent light) and ≥10 air
changes per hour.
2.3. Study Design. Core study animals were fed diets con-
taining 0, 10, 100, 1,000, 8,000, or 16,000 ppm (rats), 0, 10,
100, 1,000, 4,000, or 8,000 ppm (mice), or 0, 100, 1,000,
6,000, 12,000, or 24,000 ppm (hamsters) gemﬁbrozil for
14 weeks (N = 10). Additional groups of animals were
designated as special study animals (N = 15) and were fed
diets at the same concentrations for up to 13 weeks. For
each species, the highest exposure concentration was based
on the estimated maximum tolerated dose; in hamsters, the
NTP conducted a 14-day study prior to selecting exposure
concentrations for the 90-day study. Feed consumption by
core study animals was recorded weekly. Core and special
study animals were weighed initially, weekly, and at the end
ofthestudies.Clinicalﬁndingswererecordedweeklyforcore
and special study animals. Other endpoints were determined
as indicated below.
2.4. Clinical Chemistry. Blood for clinical chemistry was
collected from special study animals on day 34 (N = 5)
and from core study animals at the end of the studies (N =
10); animals were not fasted prior to blood collection. The
animals were anesthetized with a mixture of carbon dioxide
and oxygen, and blood was withdrawn by cardiac puncture
and placed in collection tubes devoid of anticoagulant. The
samples were allowed to clot and were then centrifuged;
the serum was removed and stored at −70
◦C until analysis.
Thefollowingclinical chemistry endpoints weremeasuredin
rats and hamsters: alanine aminotransferase (ALT), alkaline
phosphatase (ALP), sorbitol dehydrogenase (SDH), and bile
acids; mice were not evaluated for liver biomarkers due to
limited serum availability. Cholesterol and triglycerides were
measured in rats, mice, and hamsters.
2.5. Liver Histopathology and Weights. Following necropsy of
both core and special study animals, the liver was weighed.
Livers were then ﬁxed and preserved in 10% neutral buﬀered
formalin, trimmed and processed, embedded in paraﬃn,
sectioned at 5-6 microns, and stained with hematoxylin and
eosin for histopathological evaluation. Liver histopathology
was conducted on all core study rats, mice (except 10ppm),
and hamsters. The histopathological ﬁndings were subjected
to a rigorous pathology peer review including an NTP
Pathology Working Group (PWG); the ﬁnal diagnoses
represent a consensus of peer review pathologist and the
PWG.Detailsofthesereviewprocedureshavebeendescribed
by Maronpot and Boorman [45]a n dB o o r m a ne ta l .
[46].
2.6. Hepatocyte and Peroxisome Proliferation. On study days
1, 29, and 85, ﬁve special study rats, mice, and hamsters
per group were implanted subcutaneously with osmotic
minipumps (Model 2001, Alza Corp., Palo Alto, CA) pre-
ﬁlled with a 30mg/mL solution of 5-bromo-2 -deoxyuridine
(BrDU; Sigma Chemical Company, St. Louis, MO) in
0.01 N sodium hydroxide. The pumps were incubated in
phosphate-buﬀered saline at 37
◦C for at least 4 hours and
then implanted between 1300 and 1600 hours in animals
anesthetized with 2% isoﬂurane via inhalation. The exact
time of implantation in each animal was recorded. After
5 days (116 ± 3 hours) of BrDU exposure, the livers
were evaluated for incorporation of BrDU. Approximately
half of the left, right median, and anterior right lobes
were ﬁxed in 10% neutral buﬀered formalin for 48 hours;
the remaining tissue was frozen in liquid nitrogen. The
formalin-ﬁxed liver samples, as well as a transverse section of
duodenum included as an internal control, were embedded
in paraﬃn; tissues not embedded after 48 hours of ﬁxation
were transferred to 70% ethanol. Two serial sections of
each tissue were made; one slide was used for histopatho-
logic examinations, and the second slide was stained with
anti-BrDU antibody. Cell proliferation (labeled hepatocytes
as a percentage of total hepatocytes) was measured by
examining 2,000 hepatocyte nuclei from the left liver
lobe.
A sample of the left liver lobe was collected from the
BrDU animals and reserved for peroxisome proliferation
analyses; approximately 1g (rat and hamster) or 0.5g
(mouse) portions of the liver samples were prepared and
analyzed for peroxisome proliferation. Peroxisome prolif-
eration was determined in duplicate tissue extractions by
measuring β-oxidation, catalase activity, and nonspeciﬁc
carnitine acetyltransferase activity. Peroxisomal β-oxidation
was estimated by two methods: direct measurement of acyl
coenzyme A oxidase activity [47] and measurement of the β-
oxidation spiral [48]. Nonspeciﬁc carnitine acetyltransferase
activity was estimated by the method of Gray et al. [49, 50].
Peroxisomal catalase activity was estimated by a method
derived from those of Van Lente and Pepoy [51]a n d
Yasmineh et al. [52]. Protein concentrations were measured
using the bicinchoninic method with bovine serum albumin
as the standard [53]; commercially available reagents were
used.4 PPAR Research
Table 1: Survival, body weights, average daily doses, and feed consumption in male core study Harlan Sprague Dawley rats, B6C3F1 mice,
and Syrian hamsters following exposure to gemﬁbrozil in feed for 14 weeksa.
Dose
(ppm) Survival
a Initial Body
Weight
b (g)
Final Body
Weight
b (g)
Body Weight
Change
b (g)
Final Body
Weight (%
Con)
Wk 1 Feed
Consumption
(g/animal/day)
Week 13 Feed
Consumption
(g/animal/day)
Average Daily
Dose (mg/kg)
Rats
0 10/10 236 ± 3 436 ± 5 201 ± 3 — 20.9 19.1 —
10 10/10 236 ± 2 424 ± 9 189 ± 8 97 19.9 18.6 0.6
100 10/10 235 ± 2 432 ± 8 197 ± 7 99 21.5 20.8 6
1000 10/10 237 ± 3 410 ± 16 173 ± 14
∗ 94 20.2 20.1 60
8000 10/10 231 ± 3 350 ± 9∗∗ 119 ± 7∗∗ 80 13.0 19.3 510
16000 10/10 237 ± 2 286 ± 7∗∗ 49 ± 6∗∗ 66 7.5 22.8 1300
Mice
0 10/10 22.1 ± 0.13 3 .7 ± 0.61 1 .6 ± 0.5— 5 . 3 6 . 4 —
10 10/10 22.1 ± 0.23 5 .5 ± 0.81 3 .4 ± 0.6 105 6.0 5.4 1.9
100 10/10 22.1 ± 0.33 5 .1 ± 0.71 3 .0 ± 0.7 104 5.8 5.5 19
1000 10/10 21.2 ± 0.23 4 .4 ± 0.61 2 .2 ± 0.5 102 6.0 6.2 210
4000 10/10 21.5 ± 0.23 2 .0 ± 0.31 0 .5 ± 0.3 95 5.8 7.4 920
8000 10/10 22.0 ± 0.22 8 .8 ± 0.2
∗∗ 6.7 ± 0.3
∗∗ 85 5.9 7.6 2100
Hamsters
0 10/10 78 ± 1 115 ± 23 7 ± 2— 8 . 8 7 . 3 —
100 10/10 79 ± 2 125 ± 44 6 ± 4 108 8.0 7.4 7
1000 10/10 77 ± 2 118 ± 34 0 ± 2 102 7.8 7.0 80
6000 10/10 76 ± 2 120 ± 44 4 ± 4 104 7.9 6.8 480
12000 10/10 78 ± 2 109 ± 53 0 ± 5 95 7.6 7.2 970
24000 10/10 79 ± 29 9 ± 4∗∗ 20 ± 3∗∗ 86 9.7 6.3 2000
∗Signiﬁcantly diﬀerent (P ≤ .05) from the control group by Williams’ test; ∗∗P ≤ .01; aNumber of animals surviving at 3 months/number initially in group;
bMean± standard error.
2.7. Statistical Methods. The Fisher exact test [54] ,ap r o -
cedure based on the overall proportion of aﬀected ani-
mals, was used to determine the signiﬁcance of lesion
incidence. Organ and body weight data, which historically
have approximately normal distributions, were analyzed
with the parametric multiple comparison procedures of
Dunnett [55] and Williams [56, 57]. Clinical chemistry
and peroxisomal and hepatocyte proliferation data, which
have typically skewed distributions, were analyzed using the
nonparametricmultiplecomparisonmethodsofShirley[58]
(asmodiﬁedbyWilliams,[59])andDunn[60].Jonckheere’s
test [61] was used to assess the signiﬁcance of the dose-
related trends and to determine whether a trend-sensitive
test (Williams’ or Shirley’s test) was more appropriate for
pairwise comparisons than a test that does not assume a
monotonic dose-related trend (Dunnett’s or Dunn’s test).
Prior to statistical analysis, extreme values identiﬁed by the
outlier test of Dixon and Massey [62] were examined by NTP
personnel, and implausible values were eliminated from the
analysis.
3. Results andDiscussion
3.1. In Life Toxicity. All core study rats, mice, and ham-
sters survived to the end of the study. Final mean body
weight gains of rats, mice, and hamsters were decreased
by greater than 10% relative to controls at the highest two
concentrations in rats and at the highest concentration in
mice and hamsters (Table 1). Although initially reduced
at 8,000 and 16,000ppm (Table 1), feed consumption by
exposed rats was similar to that by the controls by the end
of the study (consumption was similar after week 2; data
not shown). Feed consumption by mice and hamsters was
generally similar to those by the controls; however, accurate
estimates of food consumption were diﬃcult to obtain due
to extensive scattering of feed. Average daily doses that
resulted from exposure to gemﬁbrozil are shown in Table 1.
Doses ranged from 0.6–1300mg/kg in rats, 1.9–2100mg/kg
in mice, and 7–2000mg/kg in hamsters. No chemical-
related clinical ﬁndings were observed in rats. Thinness was
observed in mice (8,000ppm) and in hamsters (2,000 and
24,000ppm). The lack of decreased food consumption or
signs of overt toxicity suggests that the decreased weight
gains of exposed animals were due to alterations in lipid
metabolism; similar ﬁndings were reported for Wy-14,643
[36].
3.2. Clinical Chemistry Analysis. Clinical chemistry data are
presented for rats, mice, and hamsters in Table 2;m i c ew e r e
not evaluated for liver biomarkers due to limited serum
availability.PPAR Research 5
Table 2: Clinical chemistry data for male Harlan Sprague Dawley rats, B6C3F1 mice, and Syrian hamsters following exposure to gemﬁbrozil
in feed for 34 days (special study) or 14 weeks (core study)a.
Rats 0ppm 10ppm 100ppm 1000ppm 8000ppm 16000ppm
n
Day 34 5 5 5 5 5 5
Week 14 10 10 10 10 10 10
ALT (IU/L)
Day 34 70 ± 56 5 ± 26 6 ± 56 7 ± 27 3 ± 4 126 ± 13
∗
Week 14 75 ± 67 1 ± 37 4 ± 5 101 ± 8∗∗ 219 ± 42
∗∗ 178 ± 16
∗∗
SDH (IU/L)
Day 34 21 ± 31 6 ± 22 4 ± 42 7 ± 42 6 ± 12 8 ± 7
Week 14 30 ± 43 1 ± 33 8 ± 35 4 ± 9∗∗ 141 ±30
∗∗ 86 ± 18
∗∗
ALP (IU/L)
Day 34 706 ± 54 642 ± 13 802 ± 32 999 ± 66
∗ 1,227 ± 66
∗∗ 1,541 ± 211
∗∗
Week 14 486 ± 19 452 ± 13 560 ± 47 788 ± 53
∗∗ 697 ± 30
∗∗ 1112 ± 50
∗∗
Bile Salts (μmol/L)
Day 34 29.4 ± 5.42 6 .4 ± 7.24 1 .4 ± 6.57 1 .6 ± 8.1
∗ 136.2 ± 11.7
∗∗ 192.8 ± 27.7
∗∗
Week 14 55.3 ± 8.23 8 .4 ± 2.95 4 .9 ± 9.17 9 .9 ± 10.4 133.4 ± 19.7
∗∗ 223.4 ± 18.0
∗∗
Cholesterol (mg/dL)
Day 34 131 ± 8 122 ± 5 150 ± 5 172 ± 5∗∗ 197 ± 11
∗∗ 223 ± 14
∗∗
Week 14 120 ± 4 122 ± 4 195 ± 9∗∗ 172 ± 8∗∗ 212 ± 5∗∗ 231 ± 5∗∗
Triglycerides (mg/dL)
Day 34 99 ± 10 91 ± 79 1 ± 87 7 ± 77 3 ± 12 84 ± 9
Week 14 124 ± 13 121 ± 7 104 ± 13 105 ± 77 2 ± 6∗∗ 58 ± 3∗∗
Mice 0ppm 10ppm 100ppm 1000ppm 4000ppm 8000ppm
Cholesterol (mg/dL)
Day 34 159 ± 8 144 ± 5 146 ± 2 144 ± 2 180 ± 6 194 ± 3
Week 14 175 ± 3 190 ± 5 184 ± 4 212 ± 6∗∗ 219 ± 5∗∗ 216 ±6∗∗
Triglycerides (mg/dL)
Day 34 142.6 ± 13.2 156.0 ± 1.47 154.8 ± 14.8 160.4 ± 5.6 122.8 ± 13.6 117.6 ± 6.6
Week 14 181.6 ± 19.8 182.1 ± 15.6 158.8 ± 10.6 134.1 ± 8.7 116.8 ± 8.8
∗∗ 100.9 ± 6.0
∗∗
Hamsters 0ppm 100ppm 1000ppm 6000ppm 12000ppm 24000ppm
ALT (IU/L)
Day 34 67 ± 13b 76 ± 14b 48 ± 1b 76 ± 7b 62 ± 11 58 ± 14
Week 14 73 ± 37 3 ± 10 86 ± 13 63 ± 67 1 ± 58 1 ± 10
SDH (IU/L)
Day 34 57 ± 11b 59 ± 83 9 ± 2b 62 ± 5b 51 ± 94 4 ± 4
Week 14 51 ± 25 9 ± 67 3 ± 21 52 ± 45 3 ± 36 5 ± 11
ALP (IU/L)
Day 34 265 ± 17b 277 ± 21b 241 ± 14b 215 ± 14b∗ 216 ± 12
∗ 190 ± 13
∗∗
Week 14 202 ± 7 192 ± 9 177 ± 15 177 ± 7 149 ± 10
∗∗ 152 ± 15
∗∗
Bile Salt (μmol/L)
Day 34 11.3 ± 0.5b 10.0 ± 1.19 .5 ± 0.9b 11.8 ± 1.4b 19.0 ± 1.44 2 .4 ±8.7
∗∗
Week 14 8.9 ± 0.71 1 .3 ± 1.3c 11.1 ± 1.8d 19.5 ± 7.32 6 .8 ± 5.7
∗ 68.6 ± 10.6
∗∗
Cholesterol (mg/dL)
Day 34 149 ± 6 143 ± 8 133 ± 5 156 ± 9 148 ± 5 152 ± 7
Week 14 149 ± 3 151 ± 8 139 ± 5 129 ± 8 153 ± 6 153 ± 7
Triglycerides (mg/dL)
Day 34 163 ± 13 171 ± 11 240 ± 27
∗∗ 263 ± 16
∗∗ 192 ± 8∗∗ 258 ± 19
∗∗
Week 14 201 ± 10 210 ± 20 203 ± 17 217 ± 21 214 ± 26 375 ± 42
∗∗
∗Signiﬁcantly diﬀerent (P ≤ .05) from the control group by Dunn’s or Shirley’s test; ∗∗P ≤ .01; aMean±standard error, statistical tests were performed on
unrounded data; bn = 4; cn = 8; dn = 9.6 PPAR Research
Table 3: Incidence and severity of liver histopathologic lesions in male core study Harlan Sprague Dawley rats, B6C3F1 mice, and Syrian
hamsters following exposure to gemﬁbrozil in feed for 14 weeksa.
Rats 0ppm 10ppm 100ppm 1000ppm 8000ppm 16000ppm
Liver, Cytoplasmic Alteration 0 7b∗∗(1.0)
c 10
∗∗ (2.0) 10
∗∗ (3.0) 10
∗∗ (4.0) 10
∗∗ (4.0)
Mice 0ppm 10ppm 100ppm 1000ppm 4000ppm 8000ppm
Liver, Cytoplasmic Alteration 0 NE 0 7∗∗ (1.0) 10
∗∗ (2.6) 10
∗∗ (3.0)
Hamsters 0ppm 100ppm 1000ppm 6000ppm 12000ppm 24000ppm
Liver, Glycogen Depletion 0 5d∗∗ (1.0) 4∗ (1.0) 8∗∗ (1.0) 9∗∗ (1.0) 10
∗∗ (2.8)
∗Signiﬁcantly diﬀerent (P ≤ .05) from the control group by the Fisher exact test; ∗∗P ≤ .01; NE = not examined; an = 10; bIncidence; cMean severity: 1 =
minimal, 2 = mild, 3 = moderate, 4 = marked; dn = 9.
Table 4: Relative liver weights in male special study Harlan Sprague Dawley rats, B6C3F1 mice, and Syrian hamsters following exposure to
gemﬁbrozil in feed for 6 days, 34 days, or 13 weeksa,b.
Rats 0ppm 10ppm 100ppm 1000ppm 8000ppm 16000ppm
Day 6 40.720 ±1.154 43.574 ±0.995 49.162 ±1.292
∗∗ 55.277 ±1.702
∗∗ 59.642 ±1.612
∗∗ 54.037 ±0.718
∗∗
Day 34 36.76 ±0.540 37.50 ±0.583 45.444 ±0.693
∗∗ 53.942 ±1.449
∗∗ 68.603 ±2.391
∗∗ 75.290 ±1.296
∗∗
Week 13 31.627 ±1.168 33.179 ±0.357 39.391 ±0.866
∗∗ 48.137 ±0.523
∗∗ 74.370 ±1.212
∗∗ 86.782 ±1.678
∗∗
Mice 0ppm 10ppm 100ppm 1000ppm 4000ppm 8000ppm
Day 6 51.954 ±0.788 50.291 ±1.108 51.703 ±2.524 54.417 ±1.465 64.524 ±1.391
∗∗ 76.920 ±0.441
∗∗
Day 34 41.768 ±1.153 45.376 ±0.687
∗∗ 47.546 ±0.742
∗∗ 51.955 ±0.327
∗∗ 63.724 ±1.036
∗∗ 72.806 ±0.749
∗∗
Week 13 41.152 ±0.390 42.606 ±0.862 41.689 ±0.737 43.299 ±1.153 60.370 ±01.303
∗∗ 71.208 ±1.235
∗∗
Hamsters 0ppm 100ppm 1000ppm 6000ppm 12000ppm 24000ppm
Day 6 5.447 ±0.286 5.119 ±0.195 5.463 ±0.384 5.448 ±0.219 5.364 ±0.157 5.214 ±0.272
Day 34 4.238 ±0.196 4.292 ±0.093 4.295 ±0.076 4.629 ±0.195 4.723 ±0.126
∗ 5.341 ± 0.106
∗∗
Week 13 3.867 ±0.086 3.718 ±0.121 3.864 ±0.122 3.940 ±0.082 4.586 ±0.067
∗∗ 5.072 ± 0.157
∗∗
∗Signiﬁcantly diﬀerent (P ≤ .05) from the control group by Dunnett’s or Williams’ test; ∗∗P ≤ .01; aData are given as mg organ weight/g body weight (mean
± standard error); bn = 5.
In rats, there was a treatment-related increase (approxi-
mately 1.8-fold) in serum alanine aminotransferase activity
at the highest concentration on day 34. By week 13, increases
(ranging between 1.4- to 2.9-fold) in alanine aminotrans-
ferase activity occurred at the top three concentrations.
Additionally, increases in sorbitol dehydrogenase activity at
thehighestthreeconcentrationsrangedfrom1.8-to4.7-fold.
Theincreasesinserumalanineaminotransferaseandsorbitol
dehydrogenase activities observed in rats would suggest a
treatment-related hepatocellular eﬀect or injury, similar to
that observed for the potent peroxisome proliferators Wy-
14,643 [36]. Increases in alkaline phosphatase activity and
bile salt concentration, suggestive of a cholestatic event,
occurred at day 34 and week 13 at the highest three
concentrations. For both variables, the increases appeared to
be dose-related, ranging between 1.4- to 2.3-fold for alkaline
phosphatase and 2.4- to 6.7-fold for bile salts. On day 34,
dose-related increases in serum cholesterol concentration
occurred at the highest three concentrations; the increases
were modest, ranging from 1.3- to 1.7-fold. By week 13,
increases in cholesterol concentration (ranging between 1.4-
to 1.9-fold) occurred in all but the lowest dose group.
Conversely, at week 13, triglyceride concentration decreased
by approximately 50% at the highest two concentrations.
In mice exposed for 13 weeks, a slight (20–30%)
treatment-related increase in cholesterol concentration
occurred at the highest three concentrations. Triglyceride
concentrations, however, were decreased at the two highest
concentrations; the decrease was dose-related at 35 and 44%
in the 4000 and 8000ppm dose groups, respectively.
In hamsters, increases in bile salt concentration, sugges-
tive of a cholestatic event, occurred on day 34 and at week 13
at the highest three concentrations; the increases appeared
to be dose-related, ranging between 1.7- to 7.7-fold. Alkaline
phosphatase activity, another marker of cholestasis, however,
was decreased at both time points at the highest three
concentrations; the decreases were modest ranging between
13 to 28%. At both time points, triglyceride concentration
was increased. At day 34, treatment- but not dose-related
increases in serum triglyceride concentration occurred in all
groups except the lowest concentration; the increases ranged
from 1.2- to 1.6-fold. By week 13, triglyceride concentration
was increased (1.9-fold) only at the highest concentration.
T h e r ew e r en oc h a n g e si nc h o l e s t e r o lc o n c e n t r a t i o n s .
There was a clear and interesting diﬀerence between
the species regarding the serum lipid (triglycerides and
cholesterol) lowering eﬀect of gemﬁbrozil. Rats and mice
had decreases in triglycerides but increases in cholesterol
concentration whereas hamsters had increases in serum
triglyceridesandnoeﬀectoncholesterolconcentrations.The
more potent peroxisome proliferator Wy-14,643 [36]h a dn o
eﬀect on cholesterol or triglycerides in rats, caused decreases
in triglycerides and increases in cholesterol (similar to gem-
ﬁbrozil in both rats and mice) in mice, and caused decreasesPPAR Research 7
Table 5:Hepatocyteproliferation(%BrdUlabeledhepatocytes)inmalespecialstudyHarlanSpragueDawleyrats,B6C3F1mice,andSyrian
hamsters following exposure to gemﬁbrozil in feed for 6 days, 34 days, or 13 weeksa,b.
Rats 0ppm 10ppm 100ppm 1000ppm 8000ppm 16000ppm
Day 6 3.740 ± 0.154 5.303 ± 0.558
∗∗ 9.333 ± 1.293
∗∗ 36.244 ± 1.692
∗∗ 26.061 ± 3.332
∗∗ 7.152 ± 0.989c∗∗
Day 34 0.783 ± 0.065 0.754 ± 0.143 0.679 ± 0.195 0.850 ± 0.199 1.300 ± 0.197 4.199 ± 0.867
∗∗
Week 13 0.451 ± 0.113 0.421 ± 0.061 0.461 ± 0.059 0.499 ± 0.076 0.608 ± 0.186 1.348 ± 0.142
∗∗
Mice 0ppm 10ppm 100ppm 1000ppm 4000ppm 8000ppm
Day 6 2.366 ± 0.345 1.414 ± 0.546 1.141 ± 0.239 1.766 ± 0.768 2.340 ± 0.842 4.449 ± 0.555
Day 34 0.896 ± 0.240 1.488 ± 0.240 1.599 ± 0.201 1.768 ± 0.385 2.097 ± 0.350 1.627 ± 0.388
Week 13 0.705 ± 0.069 1.167 ± 0.274 1.052 ± 0.157 1.240 ± 0.315 1.062 ± 0.122 0.958 ± 0.130
Hamsters 0ppm 100ppm 1000ppm 6000ppm 12000ppm 24000ppm
Day 6 2.042 ± 0.863 1.123 ± 0.117 4.323 ± 1.652 6.108 ± 3.669 2.572 ± 0.990 3.594 ± 1.598
Day 34 2.713 ± 0.582 2.148 ± 0.665 1.120 ± 0.249 3.932 ± 0.267 3.467 ± 0.962 1.566 ± 0.473
Week 13 1.176 ± 0.267 3.962 ± 0.848
∗ 4.787 ± 1.085
∗ 1.969 ± 0.169 3.625 ± 1.637 2.450 ± 0.478
∗∗Signiﬁcantly diﬀerent (P ≤ .01) from the control group by Shirley’s test; aMean±standard error; bn = 5; cn = 4; BrdU: bromodeoxyuridine.
in serum cholesterol and triglycerides in hamsters. Hamsters
are a better model for human lipoprotein metabolism that
ratsormice,ashamsters,likehumans,makecholesterolester
transfer protein (CETP) [16, 63]. In addition, hamsters have
a similar hepatic sterol synthesis rate to humans; the rate is
much higher in rats and mice [64]. It is unclear why lipid-
lowering eﬀects were not observed in hamsters following
exposure to gemﬁbrozil in the present study.
3.3. Liver Histopathology and Weights. The incidence of hep-
atocyte cytoplasmic alteration was signiﬁcantly increased in
all exposed groups of rats and in mice exposed to 1000ppm
or greater (Table 3). The severity of this lesion was increased
in rats exposed to 100ppm or greater and in mice exposed
to 4000 or 8000ppm. A dose-related increase in severity
was observed in both rats and mice. Hepatocyte cytoplas-
mic alteration was characterized by prominently increased
cytoplasmicgranularityandeosinophiliawithsomeevidence
of hepatocyte enlargement in severe cases. This change
was generally diﬀuse but in some cases, the distribution
was centrilobular to midlobular and of minimal severity.
The granularity observed in the hepatocytes was considered
consistent with the known hepatocellular appearance of
peroxisomeproliferationintheliver.Hepatocytecytoplasmic
alteration was not observed in hamsters, indicating a lack of
morphological evidence of peroxisome proliferation; how-
ever, hepatic glycogen depletion was signiﬁcantly increased
in all exposed groups and increased in severity at the
highest concentration (Table 3). Glycogen depletion was
characterizedbyadecreaseorabsenceofclearvacuolesinthe
cytoplasm of hepatocytes. The glycogen content of the liver
is variable and may ﬂuctuate depending on the physiological
state of rodents. While glycogen depletion is commonly seen
in animals that have been fasted, it may also be observed due
to the pharmacologic or toxic eﬀects of xenobiotic exposure.
Absolute and relative liver weights were recorded in
core (data not shown) and special study animals. Table 4
presents the relative liver weight data for special study
animals on day 6, day 34, and week 13. In all three species,
the maximum increase in relative liver weight was observed
at week 13. At all time points, the relative liver weights
of rats exposed to 100ppm or greater were signiﬁcantly
increased. On day 6, the largest increase was observed at
8000ppm, while the increases at 1000ppm and 16000ppm
were similar. In mice, relative liver weights were increased at
all durations at the highest two exposure concentrations and
at all concentrations on day 34. In hamsters, more modest,
but signiﬁcant increases were observed at the highest two
concentrations on day 34 and week 13. The largest increases
in relative liver weight were observed in rats (up to 2.8-fold)
and the smallest increases were in hamsters (up to 1.3-fold);
liver weights in mice were increased at up to 1.7-fold.
3.4. Hepatocyte and Peroxisome Proliferation. There were sig-
niﬁcant increases in hepatocyte cell proliferation, measured
as BrdU labeling of hepatocytes, in rats at all exposure
durations (Table 5). Cell proliferation was increased in all
e x p o s e dg r o u p so fr a t so nd a y6 .T h eg r e a t e s ti n c r e a s e sw e r e
observed in the 1000ppm (9.7 fold) and 8000ppm (7.0
fold) groups, while the increases at 100ppm (2.5 fold) and
16000ppm (1.9 fold) were similar. This pattern, which is
similar to that observed for relative liver weight on day 6, was
not observed at the day 34 and week 13 exposure durations,
as the greatest increases were at the highest concentration at
these durations. The magnitude of the maximum increase in
cell proliferation was less with increasing exposure duration
(9.7-fold on day 6, 5.4-fold on day 34, and 3.0-fold at
week 13). There were no biologically signiﬁcant increases
in hepatocyte proliferation in mice or hamsters. The lack
of an increase in mice was noteworthy, given that increases
in other endpoints were observed in both rats and mice.
In the NTP studies of Wy-14,643, increased hepatocyte
proliferation was observed in all three species at all three
exposure durations, with greater increases in rats and mice
relativetohamsters[36].Inratsandhamsters,themagnitude
of the response was lower at longer durations; however, the
response was sustained in mice. In a feed study evaluating
hepatocyte proliferation with Wy-14,643 and DEHP, at
exposure durations out to one year, a sustained proliferative
response was observed with Wy-14,643, but not DEHP [30];8 PPAR Research
Table 6: Hepatic peroxisomal enzyme activities in male special study Harlan Sprague Dawley rats, B6C3F1 mice, and Syrian hamsters
following exposure to gemﬁbrozil in feed for 6 days, 34 days, or 13 weeksa,b.
Rats 0 ppm 10 ppm 100 ppm 1000 ppm 8000 ppm 16000 ppm
Acyl CoA oxidase (nmol DCF/minute per mg)
Day 6 1.5 ±0.21 .8 ±0.71 .3 ±0.22 .0 ±0.16 .9 ±0.7
∗∗ 11.1 ± 1.0
∗∗
Day 34 1.8 ±0.21 .9 ±0.12 .5 ±0.55 .2 ±0.4
∗∗ 16.5 ±2.6
∗∗ 22.1 ± 2.4
∗∗
Week 13 1.6 ±0.11 .6 ±0.12 .9 ±0.4
∗ 6.8 ±0.5
∗∗ 27.2 ±0.9
∗∗ 33.2 ± 1.2
∗∗
β-Oxidation (Lazarow method) (nmol NADH/minute per mg)
Day 6 1.0 ±0.11 .0 ±0.11 .0 ±0.22 .3 ±0.31 2 .2 ±1.0
∗∗ 19.8 ± 2.0
∗∗
Day 34 1.2 ±0.21 .0 ±0.12 .3 ±0.3
∗ 10.0 ±1.3
∗∗ 37.9 ±6.0
∗∗ 55.8 ± 7.0
∗∗
Week 13 1.4 ±0.21 .4 ±0.12 .4 ±0.3
∗ 16.9 ±1.3
∗∗ 75.2 ±4.8
∗∗ 89.9 ± 4.2
∗∗
Carnitine acetyltransferase (nmol reduced CoA/minute per mg)
Day 6 0.8 ±0.10 .9 ±0.11 .5 ±0.5
∗∗ 2.0 ±0.1
∗∗ 11.3 ±1.2
∗∗ 15.9 ± 1.7
∗∗
Day 34 0.7 ±0.10 .7 ±0.1c 2.3 ±0.2
∗∗ 7.0 ±1.3
∗∗ 18.6 ±4.0
∗∗ 21.8 ± 3.1
∗∗
Week 13 0.6 ±0.10 .8 ±0.13 .3 ±0.9
∗∗ 13.9 ±2.3
∗∗ 55.6 ±5.2
∗∗ 42.8 ± 5.1
∗∗
Catalase (nmol NADPH/minute per mg)
Day 6 253 ±17 234 ±17 177 ±13 162 ±9 302 ±11 292 ±18
Day 34 289 ±23 253 ±16 222 ±18 329 ±29 438 ±30
∗ 476 ± 26
∗
Week 13 274 ±28 281 ±6.0 253 ±22 378 ±28
∗ 523 ±24
∗∗ 508 ±29
∗∗
Mice 0ppm 10ppm 100ppm 1000ppm 4000ppm 8000ppm
Acyl CoA oxidase (nmol DCF/minute per mg)
Day 6 1.2 ±0.11 .0 ±0.01 .1 ±0.12 .5 ±0.1
∗ 8.2 ±1.8
∗∗ 16.5 ±2.2
∗∗
Day 34 1.2 ±0.11 .4 ±0.21 .0 ±0.32 .7 ±0.5
∗ 8.5 ±0.7
∗∗ 15.5 ±0.4
∗∗
Week 13 1.2 ±0.11 .4 ±0.11 .1 ±0.11 .7 ±0.1
∗ 10.9 ±1.3
∗∗ 18.0 ±1.7
∗∗
β-Oxidation (Lazarow method) (nmol NADH/minute per mg)
Day 6 0.5 ±0.2c 1.0 ±0.20 .8 ±0.21 .9 ±0.1c∗∗ 15.3 ±0.5c∗∗ 30.6 ±1.3
∗∗
Day 34 1.0 ±0.31 .0 ±0.20 .9 ±0.1c 1.9 ±0.1
∗ 19.8 ±1.1
∗∗ 45.4 ±1.3
∗∗
Week 13 1.2 ±0.1c 1.2 ±0.11 .2 ±0.21 .9 ±0.22 1 .3 ±0.6
∗∗ 42.2 ±1.5
∗∗
Carnitine acetyltransferase (nmol reduced CoA/minute per mg)
Day 6 1.2 ±0.11 .4 ±0.21 .4 ±0.12 .6 ±0.3
∗∗ 11.1 ±2.0
∗∗ 17.2 ±0.5
∗∗
Day 34 1.7 ±0.21 .3 ±0.11 .2 ±0.12 .7 ±0.31 5 .7 ±1.3
∗ 24.6 ±1.4
∗∗
Week 13 1.5 ±0.21 .7 ±0.11 .8 ±0.32 .8 ±0.3
∗∗ 18.1 ±0.9
∗∗ 24.8 ±1.0
∗∗
Catalase (nmol NADPH/minute per mg)
Day 6 98.3 ±6.29 6 .8 ±4.29 5 .8 ±2.89 6 .0 ±2.6 187.8 ±27.4 314.7 ±8.7
∗∗
Day 34 98.3 ±4.08 8 .1 ±3.98 6 .6 ±3.88 9 .3 ±6.3 225.9 ±8.8 289.2 ±4.3
∗∗
Week 13 74.8 ±4.47 5 .4 ±7.18 4 .2 ±10.57 8 .7 ±7.4 238.8 ±8.4
∗∗ 302.1 ±11.3
∗∗
Hamsters 0ppm 100ppm 1000ppm 6000ppm 12000ppm 24000ppm
Acyl CoA oxidase (nmol DCF/minute per mg)
Day 6 2.4 ±0.22 .1 ±0.12 .5 ±0.23 .1 ±0.44 .0 ±0.2
∗ 4.4 ±0.6
∗
Day 34 2.1 ±0.22 .3 ±0.22 .3 ±0.23 .1 ±0.2
∗ 3.2 ±0.3
∗ 4.6 ±0.4
∗∗
Week 13 2.2 ±0.12 .2 ±0.12 .1 ±0.12 .9 ±0.1
∗∗ 3.2 ±0.2c∗∗ 3.7 ±0.4
∗∗
β-Oxidation (Lazarow method) (nmol NADH/minute per mg)
Day 6 1.9 ±0.11 .9 ±0.51 .7 ±0.12 .2 ±0.4d 2.7 ±0.2c 3.0 ±0.2
∗∗
Day 34 2.2 ±0.11 .8 ±0.32 .0 ±0.32 .0 ±0.21 .6 ±0.3c 2.0e
Week 13 2.1 ±0.12 .0 ±0.11 .6 ±0.31 .6 ±0.22 .0 ±0.2c 2.2 ±0.5f
Carnitine acetyltransferase (nmol reduced CoA/minute per mg)
Day 6 8.0 ±0.58 .1 ±0.27 .6 ±0.61 0 .8 ±0.4
∗∗ 12.8 ±0.9
∗∗ 14.1 ±1.6
∗∗
Day 34 7.0 ±0.26 .1 ±0.28 .2 ±0.57 .4 ±0.49 .3 ±0.4
∗ 17.2 ±2.1
∗∗
Week 13 6.8 ±0.46 .0 ±0.27 .5 ±0.88 .2 ±0.31 0 .8 ±2.0
∗ 14.1 ±2.2
∗∗PPAR Research 9
Table 6: Continued.
Rats 0 ppm 10 ppm 100 ppm 1000 ppm 8000 ppm 16000 ppm
Catalase (nmol NADPH/minute per mg)
Day 6 273 ±21 304 ±9 249 ±25 260 ±37c 251 ±17 226 ±11
Day 34 302 ±24 312 ±22 285 ±12 284 ±22 258 ±16 261 ±34
Week 13 291 ±19 272 ±17 269 ±26 270 ±10 246 ±14 252 ±13c
∗∗Signiﬁcantly diﬀerent (P ≤ .01) from the control group by Shirley’s test; aMean ± standard error; bn = 5; cn = 4; dn = 3; en = 1, no standard error
presented because only one sample available; fn = 2.
thissustainedproliferationwithWy-14,643islikelyreﬂective
of its potency. The lack of a sustained proliferative response
in rats with gemﬁbrozil in the present study is similar to that
observed with DEHP and other peroxisome proliferators,
indicating less potency relative to Wy-14,643.
Peroxisomal enzyme activities are shown in Table 6.I n
rats, mice, and hamsters, Acyl CoA Oxidase, β-oxidation,
andcarnitine acetyltransferaseweregenerallyincreasedwith
increasing concentration; however, the eﬀect was not as pro-
nounced in hamsters. In rats and mice, the greatest increases
relative to controls were generally observed at week 13. In
rats, these enzymes were increased at 100ppm or greater by
week 13. In mice, these enzymes were generally increased
at the highest three concentrations. In hamsters, Acyl CoA
oxidase and carnitine acetyltransferase were increased at the
highest two concentrations at all durations and at the highest
three concentrations on day 34 and week 13 (Acyl CoA
oxidase) or day 6 (carnitine acetyltransferase). β-oxidation
was increased only at the top two concentrations on day
6. Maximum increases in Acyl CoA oxidase and carnitine
acetyltransferase were similar between rats and mice, while
the increase in β-oxidation in rats was much greater than
in mice. In general, increases in catalase were observed only
at higher concentrations and longer durations relative to
the other enzymes in rats and mice; the lower induction of
catalase relative to hydrogen peroxide generating enzymes is
consistent with previous reports. Increases in catalase were
not observed in hamsters. The greater observed increases in
hydrogen peroxide generating enzymes relative to increases
in catalase, which removes hydrogen peroxide, are consistent
with previous studies on peroxisome proliferators, support-
ing the hypothesis that hepatocarcinogenesis may arise due
to a net increase in hydrogen peroxide and subsequent
oxidative stress. A generally similar pattern of increased
enzyme activities was observed with Wy-14,643 [36]e x c e p t
that responses occurred at lower concentrations.
3.5. Comparison of Results with Gemﬁbrozil Cancer Bioassay.
In a previous cancer bioassay of gemﬁbrozil [12], male and
female albino CD rats and CD-1 mice were exposed to 0,
30, or 300mg/kg for 104 weeks (rats) or 78 weeks (mice).
The authors stated that gemﬁbrozil was a liver carcinogen
in male rats, but not in female rats or in mice of either sex.
In rats, there was a clear and signiﬁcant increase in benign
liver neoplastic nodules at 300mg/kg and an increased
n u m b e ro fl i v e rc a r c i n o m a sa tb o t h3 0a n d3 0 0 m g / k g .
In mice, there was a signiﬁcant increase in hepatocellular
carcinomas at 30mg/kg, but not 300mg/kg. In the present
study, a dose of 300mg/kg would result from exposure to
between 1000 (60mg/kg) and 8000 (510mg/kg) ppm in rats
and 1000 (210mg/kg) and 4000 (920mg/kg) ppm in mice.
At these concentrations, signiﬁcant increases in hepatocyte
cytoplasmic alteration, relative liver weights, hepatocyte
proliferation (rats only), and hydrogen peroxide producing
peroxisomal enzyme activities were increased. In general,
despite the fact that the dose range was higher in mice than
inrats,thereweregreaterincreasesintheseendpointsinrats;
thisisespeciallythecasewithhepatocyteproliferation,which
was not increased in exposed mice. Thus, it appears that
the species susceptibility to liver tumors correlates with that
ofperoxisome-proliferation-relatedhepaticeﬀects.However,
the observed diﬀerences in response may be the result of
diﬀerent exposure durations.
3.6. Studies by Investigators Utilizing NTP Tissues. Several
investigators utilized tissues from the NTP peroxisome
project studies to evaluate mechanisms of peroxisome
proliferator-induced hepatocarcinogenicity with selected
compounds. These studies typically evaluated oxidative
stress-related mechanisms of action. Diﬀerences in species
susceptibility between rats and hamsters were observed with
severalendpoints,includingseleniumdependentglutathione
peroxidase activity, which was increased in hamsters and
decreased in rats following exposure to Wy-14,643, GEM,
and DBP [38]; activation of NFkappaB, occurred in rats
primarily with Wy-14,643 but to a lesser extent with Gem
and DBP, but not in hamsters [39]; and polymerase-β,R e f -
1, and PNCA were increased in rats but either observed
at trace levels (polymerase-β) or decreased (Ref-1 and
PCNA) in hamsters, following exposure to Wy-14,643 [42].
In contrast, some endpoints did not reﬂect species diﬀer-
ences, including glutathione-S-transferase and glutathione
reductase activities following exposure to Wy-14,643 and
DBP [38], activation of several redox-sensitive transcription
factors, including AP-1 early growth response gene 1 and
heat shock factors 1 and 2 following exposure to Wy-
14,643, GEM or DBP [40], expression of the proapoptotic
protein Bax following exposure to Wy-14,643, GEM, and
DBP [42], and antioxidant capacities with dibutyl phthalate,
gemﬁbrozil, or Wy-14,643 [41]. Exposure of rats and mice to
Wy-14,643 increased the expression of several base excision
repair enzymes, but not the expression of enzymes that are
not involved in the repair of oxidative DNA damage [44].
The other compounds induced weaker or no increases in the
expression of these enzymes. In another study, WY, Gem,
DBP, and 2,4-D were evaluated for their ability to alter the10 PPAR Research
methylation and expression of the c-myc protooncogene
in mice [43]. All four peroxisome proliferators caused
hypomethylation of the c-myc gene in the liver, while only
Wy-14,643 increased the level of c-myc protein. Collectively,
these studies provide some insight regarding oxidative stress-
related mechanisms of peroxisome proliferators and species
diﬀerences in susceptibility.
3.7. Comparison of PPARα-Mediated Eﬀects in Rodents and
Humans. Recent studies by Gonzalez and colleagues using
humanizedPPARαmicehaveprovided someinformation on
the mechanism of PPARα-hepatocarcinogenicity in rodents
and species diﬀerences between rodents and humans fol-
lowing exposure to rodent peroxisome proliferators [25,
26, 32, 34, 35]. Hepatocellular proliferation and neoplasms
were observed in wild type, but not humanized PPARα
mice. A proposed mechanism of the hepatic proliferative
eﬀects involves downregulation of let-7C miRNA, resulting
in the increased expression of c-myc, which in turn results
in increased hepatocellular proliferation and tumors [26,
34, 35]. In contrast, these biochemical and morphologic
eﬀects are not observed in humanized PPARα mice. In mice
with both receptor types, induction of genes involved in
peroxisomal and mitochondrial β-oxidation were observed.
These data may explain the diﬀerence in PPARα-mediated
eﬀects between rodents and humans.
Several studies evaluated the pleiotropic responses to
prolonged (from14 days up to 13 weeks) oral administration
of relatively high doses of peroxisome proliferators (500 to
2500mg/kg) in several species of nonhuman primates [65–
67]. In contrast to results found in rodents, no signiﬁcant
increases in liver weight, induction of peroxisomal enzymes,
or proliferation of peroxisomes were reported. Studies that
examined patients treated with relatively more potent PPs
(e.g., cloﬁbrate, gemﬁbrozil, or fenoﬁbrate), for prolonged
periods of time (i.e., years) are more consistent with the
idea that humans do not exhibit peroxisome proliferation
in response to exposure to PPs. Similar to ﬁndings made in
hemodialysis patients, a marginal 50% increase in liver per-
oxisome number, but not in peroxisome volume, is reported
in humans treated with cloﬁbrate [68]. In contrast, the
majorityofstudiesexaminingtheeﬀectofPPadministration
in humans have consistently shown no change in hepatic
peroxisome proliferation in liver (reviewed in [24]).
There are no known reports of long-term carcinogenesis
studies with PPs in nonhuman primates. Several large epi-
demiological studies that examined the relationship between
chronic treatment with lipid-lowering PPs gemﬁbrozil and
cloﬁbrate did not ﬁnd an association with liver cancer
(reviewed in [24]). Collectively, human epidemiological
studies have not shown an association between liver cancer
and treatment with PPs [69].
The molecular mechanism by which hypolipidemic
ﬁbrates and antidiabetic thiazolidinediones exert their thera-
peuticeﬀect in humans is similar to the way peroxisome pro-
liferators exert their toxicity in rodents, namely, by activation
of the PPAR family of receptors. In response to exposure to
a PP chemical, the mRNA and protein levels of numerous
enzymes are increased in rodents, including the enzymes
in the peroxisome per se but also microsomal cytochrome
CYP4A. Primary organs involved in this pleiotropic response
are liver, kidney, and heart. A receptor responsible for
activating these diverse eﬀects was identiﬁed, termed the
peroxisome proliferator-activated receptor (PPAR) and was
demonstrated to belong to the nuclear receptor superfamily
that includes the estrogen, progesterone, and retinoic acid
receptors. Members of the PPAR family of receptors include
PPARα,P P A R β/δ,a n dP P A R γ, which have diﬀerent tissue
distributions, abundances and functions in lipid metabolism
during diﬀerent stages of development. PPARγ mRNA has
been detected in greatest amounts in human heart, placenta,
lung, and kidney, but has also been identiﬁed in human
prostate, testis, and ovary [70, 71].
PPARα mediates gene activation through binding to a
DNA response element (PPRE) (a DR-1 response element)
upstream from all genes that are known to respond to
PPs. These include genes in the peroxisome mentioned
above as well as cytochromes CYP4A and fatty acid binding
protein. The other members of the PPAR superfamily
(PPARβ/δ and γ) bind to and activate similar PPRE but in
diﬀerent tissues. PPAR-ligand complex binds to the PPRE
upstream of the LPL and Apo A I and -II genes in humans,
whereas it binds upstream and activates diﬀerent genes in
rodents, namely, those genes responsible for the peroxisome
proliferation response. The increased lipoprotein lipase and
apolipoprotein (apo) A-I and apoA-II induction increase
plasma HDL and increase triglyceride mobilization. In
rats PPARα activation decreases apoA-I and apoA-II gene
expression and lowers plasma HDL [72]. In humans, HDL
cholesterol is elevated after ﬁbrate treatment due to increased
lipolysis of triglyceride-rich lipoproteins and redistribution
of lipid components to HDL.
Although the PPRE is almost identical in rodents
(TGCCCTTCCCCC) and humans (TGCCCTTCCCCC), the
location in the genome of the PPRE is diﬀerent across
species resulting in vastly diﬀerent genes expressed following
activation of the PPAR family.
The human receptor appears to be activated by certain
fatty acids and eicosanoids and thiazolidinedione antidia-
betic drugs, although it appears to be only weakly activated
by classical PPs such as, Wyeth-14,643 nafenopin and
cloﬁbric acid [71]. Endogenous ligands for PPARs include
most straight-chain fatty acids, substituted fatty acids, and
the acyl-CoA esters of fatty acids, and arachidonic acid
derived prostaglandins and eicosanoids [73].
In humans, like rodents, ﬁbrate drugs used in the
treatment of hyperlipidemia are thought to activate PPARα
in the liver. However, unlike rodents, activation of PPARa
in humans does not result in peroxisome proliferation
but results in increased apolipoprotein A-II and lipopro-
tein lipase transcription, and reduced apolipoprotein C-
III, which is key to their mechanism of action to lower
serum triglycerides [74–76] as well as induction of fatty acid
transport protein and acyl-CoA synthetase [77]. (Apo C-
III is a major component of very low-density lipoproteins
(VLDL)andinhibitslipoproteinlipaseandinhibitsclearance
of lipoproteins by the liver).PPAR Research 11
The antidiabetic agents in the thiazolidinediones activate
human PPARγ in adipose tissue where lipoprotein lipase
expressionisalsoincreased.LPListranscriptionallyactivated
and results in increased lipolytic activity and a decrease
in serum triglycerides in humans without an increase in
peroxisomeactivityseeninrodents,againduetothelocation
of the PPARγ response element upstream of the LPL gene
[75].
4. Conclusions
The present NTP studies conﬁrm the induction of hep-
atomegaly and hepatocyte and peroxisome proliferation
and alteration of lipids following exposure to gemﬁbrozil.
Similar to NTP studies with Wy-14,643 [36], these studies
also present data on hamsters, which were considered, like
humans, to be nonresponsive to PPARα-mediated eﬀects on
hepatic and peroxisome proliferation, similar to primates
and humans. Based on these data, it is apparent that rats are
most responsive to the hepatic eﬀects of gemﬁbrozil, while
mice are intermediate and hamsters are the least responsive;
however, the increases in peroxisomal enzymes indicate
peroxisome proliferation is induced in hamsters. In all three
species, the pattern of peroxisomal enzyme is consistent
with previous reports, with greater increases in hydrogen
peroxide-generating enzymes compared to catalase. The
greater sensitivity to the induction of hepatic peroxisome
and hepatocellular proliferation in rats compared to mice
may explain the diﬀerences in liver carcinogenicity between
the two species observed in a previous study. Gemﬁbrozil
produced alterations of lipid metabolism in each species;
the eﬀects and rats and mice were similar and distinct from
hamsters.
It is clear from several investigators that humans possess
a functional PPAR family of receptors. It is also clear that
they regulate diﬀerent genes relative to the receptor family
in rodents, and that the human PPAR receptor is activated
by xenobiotic drugs and chemicals. What is less clear is
the relative potency of phthalates to activate the hPPAR
family compared to therapeutic agents as well as compared
to endogenous activators, and what such activation, if any,
would result that may have deleterious eﬀects in humans
[11]. Indeed, in two recent reviews of the medical signif-
icance of PPARs, it was reported that since PPAR does
not induce peroxisomes in humans the term peroxisome
proliferator per se in a medical context is a misnomer
([21, 78] and references contained therein). An excellent
review of the mechanism of action of ﬁbrates in humans
waspublishedrecently[79].Recentlypublishedstudiesusing
humanized PPARα mice have provided mechanistic insights
into the observed hepatocarcinogenicity in rodents and on
diﬀerences between rodents and humans [25, 26, 32, 34, 35].
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